TrialCurrent oncology (Toronto, Ont.)2024

A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant.

Richard LeBlanc et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.